US Earnings Financial Results SEC Filings — March 20, 2026

20-03-2026

Wellgistics Health, Inc.'s 10-K filing describes its business operations across distribution, third-party logistics, and the DelivMeds digital pharmacy platform, supported by a network of over 5,000 pharmacies and facilities in Florida and Ohio. Acquisition-related consideration for Wellgistics LLC and Wood Sage includes $10M cash, $15M promissory note, and up to $25M in stock bonuses, with contingents tied to EBITDA targets through 2026. However, the filing emphasizes extensive risks including integration difficulties, reimbursement reductions, margin compression, and competitive pressures, with no financial performance metrics provided.

• ·Primary distribution center in Lakeland, Florida; additional facility in Columbus, Ohio; main office in Tampa, Florida.
• ·Contingent bonuses: 50% cash and 50% common stock if EBITDA exceeds 110% of targets for years ended Dec 31, 2024, 2025, and 2026.
• ·Promissory note interest: simple interest at Prime Rate as published by Wall Street Journal on Jan 1 of applicable year, payable in three equal annual installments starting first anniversary of registration effectiveness.
• ·Remainder of $10M cash due no later than earlier of 45 days post-registration effectiveness or Aug 30, 2025.

20-03-2026

Aeva Technologies reported revenue of $18.1M for FY 2025, nearly doubling 99% YoY from $9.1M, with North America contributing 74% of revenue, while gross loss narrowed 83% to $0.7M. However, net loss improved only 4% to $145.4M from $152.3M amid a $21.5M negative change in warrant liability and high R&D expenses of $85.4M (down 17% YoY), leading to stockholders' equity dropping sharply to $13.2M from $99.4M due to $96.7M in new convertible notes. Cash and equivalents rose to $72.3M, supported by $128.6M in financing inflows.

• ·Revenue by geography FY2025: North America $13.3M (74%), Europe $3.9M (21%), Asia $0.6M (3%).
• ·Cash from financing FY2025: $128.6M primarily from $100M convertible notes and $32.5M private placement.
• ·Marketable securities declined to $49.6M from $83.1M as of Dec 31 2025.
• ·Weighted-average shares basic/diluted: 57.0M in FY2025 vs 53.4M in FY2024; net loss per share $(2.55) vs $(2.85).

20-03-2026

Appendix B of the 10-K provides servicing criteria compliance disclosures under Regulation AB for asset-backed securities, detailing how criteria are handled by Unknown Company, PBLS1, CoreLogic, and Midland—mostly performed directly or by responsible vendors/subservicers. Several criteria are marked as inapplicable or not performed, such as maintaining back-up servicers (1122(d)(1)(iii)), certain investor reporting reconciliations (e.g., 1122(d)(3)(i)(B)-(D)), and external enhancements (1122(d)(4)(xv)). No quantitative performance metrics, deficiencies, or exceptions are reported.

• ·Filing date: March 20, 2026
• ·Standard timeframes referenced include deposits/postings within 2 business days, reconciliations within 30 calendar days, and resolution of reconciling items within 90 calendar days

20-03-2026

Belpointe PREP, LLC reported total assets of $564.2M as of Dec 31, 2025, up 9% YoY from $517.6M, driven by real estate net growth to $531.9M (+10% YoY), while revenue surged 244% YoY to $9.2M. However, net loss attributable to the company widened 68% YoY to $40.0M from $23.9M, with loss per Class A unit deteriorating to $(10.72) from $(6.56), amid higher debt ($260.6M, +47% YoY), elevated interest expense (+74% YoY), and negative NOI across Commercial (-$1.1M) and Mixed-use (-$1.3M) segments.

• ·Cash flows used in operating activities worsened to $(25.2M) in 2025 from $(13.7M) in 2024.
• ·Cash flows from financing activities declined to $87.0M in 2025 from $157.0M in 2024, leading to a net cash decrease of $0.2M.
• ·Commercial Segment NOI: $(1.1M) in 2025 vs $(0.05M) in 2024; Mixed-use Segment NOI: $(1.3M) in 2025 vs $(1.4M) in 2024 (slight improvement but still negative).

20-03-2026

Pelican Acquisition Corp, a SPAC, reported net income of $1.25M for the year ended January 31, 2026, compared to a $42.6k loss in the prior inception-to-January 31, 2025 period, primarily driven by $2.35M in interest income from its newly funded $88.6M Trust Account holding 8,625,000 redeemable shares at $10.27 per share post-IPO. However, general and administrative expenses surged to $1.1M from $43k, leading to a $1.1M operational loss, while shareholders' deficit widened to $(405k) from $(13k). Total assets grew to $88.8M from $208k, reflecting IPO proceeds, but cash remained minimal at $77.

• ·Promissory note – related party: $0 at Jan 31, 2026 (down from $200k at Jan 31, 2025)
• ·Due to target company (Greenland): $100k as of Jan 31, 2026
• ·IPO-related: Private Placement Units issuance raised $2.99M; Public Rights net $1.34M
• ·Remeasurement of carrying value to redemption value: $(4.5M) and $(888k); Accretion $(792k)

20-03-2026

Yellowstone MidCo Holdings II, LLC reported revenue growth of 52% YoY to $386M for 2025 from $254M in 2024, with gross profit tripling to $75M (20% margin from 13%) and Adjusted EBITDA improving to -$8M from -$43M. However, the company posted a net loss of $85M (narrowed 15% YoY), operating expenses increased 17% driven by higher SG&A (+11%) and transaction costs, R&D declined 10%, and net cash used in operations was $121M versus provided by $32M prior year.

• ·Net EAC adjustments before taxes: -$11.1M in 2025 vs -$22.9M in 2024.
• ·Minimum revenue guarantees extend to Sep 2028 at $758M.
• ·Cash increased $58M to $163M end-2025, driven by $204M financing inflows.

20-03-2026

Firefly Aerospace reported revenue of $159.9M for 2025, up 163% YoY from $60.8M, driven by strong growth in Spacecraft Solutions (+244% to $131.2M) and Launch revenue (+26% to $28.6M); gross profit swung to $30.7M from a $11.4M loss. However, net loss widened 29% YoY to $298.3M, operating loss increased 24% to $260.7M amid 47% higher operating expenses, and cash used in operations rose 30% to $204.9M, though bolstered by $1.3B in financing inflows.

• ·Adjusted EBITDA was -$198.6M in 2025, worsening from -$190.6M in 2024.
• ·Free cash flow was -$237.8M in 2025, down from -$190.3M in 2024.
• ·Total assets grew to $1.8B from $407.3M; cash equivalents rose to $793M from $123.4M.
• ·Intangible assets $165.7M and goodwill $450.1M as of Dec 31 2025, primarily from acquisitions.
• ·Net loss per common share improved to -$4.83 from -$20.74, with weighted-average shares 69,204 vs 12,819.

20-03-2026

Dollar General's FY2025 net sales rose 5.2% YoY to $42.7B from $40.6B in FY2024, driven by 6.7% growth in home products and 6.2% in seasonal, while consumables grew 5.0% and apparel a modest 3.3%; average sales per square foot increased to $270 from $263. Operating profit surged 28.6% to $2.2B with gross margin expanding 107 bps to 30.66%, and net income climbed 34.4% to $1.5B. However, profitability metrics remained below FY2023 levels, with operating profit down 29.9% from $2.4B and net margin at 3.54% versus 4.29%.

• ·Average sales per square foot: $270 in FY2025 (up from $263 in FY2024)
• ·FY2025 SG&A expenses: $10.9B (5.8% YoY increase)
• ·FY2025 diluted EPS: $6.85 (34.1% YoY increase from $5.11)
• ·Self-insurance liabilities: $377.6M total

20-03-2026

Milestone Pharmaceuticals reported first-year revenue of $1.5M for the year ended December 31, 2025, up 100% from $0 in 2024 following the US launch of CARDAMYST nasal spray, supported by a sales team of approximately 60 representatives targeting cardiology and primary care providers for an estimated 500,000 PSVT patients in 2026. However, total operating expenses rose 51.3% to $63.7M, driven by a 157.2% surge in commercial expenses to $28.3M and 26.1% increase in R&D to $18.1M, resulting in a widened net loss of $63.1M (51.9% worse than $41.5M in 2024). The company anticipates continued substantial operating losses until CARDAMYST revenue suffices.

• ·Company has incurred significant operating losses since inception and anticipates continued losses until CARDAMYST revenue is sufficient.
• ·Pursuing clinical development for subsequent etripamil indications beyond PSVT.

20-03-2026

Victoria's Secret & Co. reported fiscal 2025 net sales of $6,553M, up 5% YoY from $6,230M, driven by 27% growth in International sales and 3% in North America stores, while Direct sales remained flat at $2,042M. Adjusted operating income increased 8% to $403M and adjusted net income rose 15% to $250M with EPS at $3.00 (up from $2.69); however, GAAP reported operating income declined 13% to $271M from $310M and net income edged down 2% to $161M due to a $120M Adore Me long-lived assets impairment and other restructuring charges. Productivity improved with sales per average selling square foot up 6% to $624 and per store up 7% to $4.3M, though total selling square feet fell 2%.

• ·Capital expenditures fiscal 2025: $187M (up from $178M)
• ·Long-term debt stable at $971M as of Jan 31, 2026 (vs $973M prior year)
• ·Amounts available under ABL Facility: $589M (up from $533M)
• ·Total selling square feet: 5,315 thousand (down 2% YoY)
• ·Future lease obligations total $2,452M, with $416M due within 1 year
• ·Purchase obligations: $877M, mostly due within 1 year ($817M)

20-03-2026

Bluerock Acquisition Corp., a SPAC, reported total assets of $173.6M as of December 31, 2025 (period from inception on July 11, 2025), with $172.7M held in the Trust Account from 17.25M Class A ordinary shares at $10.01 per share, indicating intact IPO proceeds. However, the company shows a shareholders' deficit of $6.6M driven by an accumulated deficit, alongside $7.4M in total liabilities including a $7.35M deferred underwriting fee and only $0.7M cash outside the trust.

• ·Prepaid insurance: $66,500 (current) + $63,729 (long-term)
• ·Accrued offering costs: $75,000
• ·Total current assets outside trust: $781,394
• ·Filing date: March 20, 2026 for period July 11, 2025 (inception) to December 31, 2025

20-03-2026

Jackson Acquisition Co II, a SPAC, reported net income of $9.1M for the year ended December 31, 2025, driven by $9.7M in interest income from the Trust Account, which grew to $242.5M (4.2% increase) at a redemption value of $10.55 per share from $232.9M at $10.12 per share as of December 31, 2024. However, operating losses widened to $0.57M from $0.18M, cash balances declined 45% to $0.52M, and shareholders' equity fell 72% to $0.22M amid accretion to public shares.

• ·Business combination must be completed by December 11, 2026, or public shares redeemed from Trust Account
• ·Initial shareholders, directors, and officers waived redemption rights on founder and public shares held by them
• ·Founder shares non-transferable until 1 year post-business combination or $12.00/share trigger met
• ·Private Placement Units non-transferable until 30 days post-business combination and expire worthless if no combination

20-03-2026

Snowflake Inc. reported FY2026 total revenue of $4.68B, up 29% YoY from $3.63B, driven by 29% product revenue growth to $4.47B, strong operating cash flow of $1.22B (up 27% YoY), and RPO expansion to $9.77B (up 42% YoY), alongside customer growth with $1M+ ACV customers rising 27% to 733. However, net retention rate declined to 125% from 126% YoY and 133% in FY2024, operating loss narrowed slightly to $1.44B from $1.46B but remained elevated, and net loss attributable to Snowflake widened 4% YoY to $1.33B amid high operating expenses and $1.60B in stock-based compensation.

• ·Gross margin stable at 67% in FY2026 vs FY2025.
• ·Sales and marketing expenses as % of revenue improved to 44% from 46% YoY.
• ·Research and development expenses as % of revenue declined to 42% from 49% YoY.
• ·Net cash used in financing activities increased to $1.39B in FY2026 from $0.23B.

20-03-2026

For the three months ended February 28, 2026, Scholastic Corp reported revenues of $329.1M, down 1.9% YoY from $335.4M amid declines across most segments, with operating loss widening slightly to $(26.9)M from $(23.9)M; however, a one-time $119.8M gain on sale-leaseback transactions swung net income to $62.5M from a $3.6M loss. Over nine months, revenues fell 1.0% YoY to $1,105.8M, operating loss narrowed marginally to $(36.2)M from $(37.7)M for net income of $47.3M versus a $17.3M loss, though Education Solutions plummeted 14% to $158.4M while Children's Book Publishing and Distribution grew 1.8% to $687.9M.

• ·Long-term debt reduced to $0 as of February 28, 2026 from $250M at May 31, 2025.
• ·Total assets decreased to $1,780.8M from $1,950.1M at May 31, 2025.
• ·Cash and cash equivalents at $104.6M, down from $124.0M at May 31, 2025.
• ·Net cash used in operating activities $39.1M for nine months vs provided $17.3M prior year.
• ·Quarterly dividend of $0.20 per share declared and paid.
• ·Property, plant and equipment, net dropped to $193.7M from $516.3M due to sale-leaseback.

20-03-2026

Mountain Lake Acquisition Corp. II (MLAA), a blank check company with no operating history or revenues, filed its 10-K Annual Report covering the period from inception on October 16, 2025, through December 31, 2025, highlighting risks such as limited shareholder evaluation basis and potential negative interest rates on Trust Account investments. The Sponsor or affiliates may provide up to $1.5M in Working Capital Loans to finance transaction costs for a Business Combination, convertible into units at $10.00 per unit. Post-combination, operations may be heavily reliant on foreign assets and revenues, exposing results to economic and political risks in such countries.

• ·Financial statements include Balance Sheet as of December 31, 2025, and Statements of Operations, Changes in Shareholder’s Deficit, and Cash Flows for the period October 16, 2025 (inception) through December 31, 2025.
• ·Report of Independent Registered Public Accounting Firm (PCAOB ID Number 100).

20-03-2026

Bain Capital GSS Investment Corp. (BCSS-WT) filed its 10-K annual report on March 20, 2026, presenting financial statements for the period from inception on March 24, 2025, through December 31, 2025, including balance sheet, statement of operations, changes in shareholders' deficit, and cash flows. The filing defines key terms such as private placement units, shares, and warrants issued to the sponsor simultaneously with the initial public offering and notes potential post-business combination risks like change in control or debt burdens. No operational performance metrics or period-over-period comparisons are detailed in the provided content.

• ·Financial statements as of December 31, 2025, and for the period March 24, 2025 (inception) through December 31, 2025
• ·Includes Report of Independent Registered Public Accounting Firm and Notes to Financial Statements (F-7 to F-18)

20-03-2026

Palisade Bio, Inc. reported a widened net loss of $16.8M for the year ended December 31, 2025, up 16% YoY from $14.4M, driven by a 22% increase in total operating expenses to $18.1M (R&D up 12% to $10.2M, G&A up 36% to $7.9M). However, cash and equivalents surged to $133.4M from $9.8M, fueled by $134.4M in net financing activities primarily from equity offerings and warrant exercises, while cash used in operations improved slightly to $10.8M from $12.2M.

• ·Basic and diluted net loss per common share improved to $(0.30) from $(10.19) YoY due to increased share count.
• ·Total assets increased to $134.3M from $10.9M; stockholders' equity to $129.4M from $7.5M.
• ·Stock-based compensation expense rose to $4.0M from $0.7M.
• ·Proceeds from issuance of common stock and warrants net: $128.2M in 2025 vs $8.4M in 2024.

20-03-2026

Armada Acquisition Corp. III (AACI), a blank-check SPAC focused on FinTech opportunities, reported total assets of $332,011 and cash of $4,347 as of December 31, 2025, for the period from inception on September 19, 2025. The company recorded a net loss of $52,950, resulting in a shareholders' deficit of $27,950, driven by general and administrative costs. It highlighted strong FinTech market growth, projecting the global market to expand from $340B in 2024 to $1,152B by 2032 at a 16.5% CAGR.

• ·Deferred offering costs: $327,664 as of Dec 31, 2025
• ·Accrued offering costs: $291,930 as of Dec 31, 2025
• ·Basic and diluted net loss per Class B ordinary share: $(0.01)
• ·Global FinTech market valued at $295B in 2023 per Fortune Business Insights

20-03-2026

Chain Bridge Bancorp reported net income of $20.2M for the year ended December 31, 2025, down 3.4% YoY from $20.9M in 2024, driven by a sharp 59.4% decline in noninterest income to $3.5M despite robust 16.1% growth in net interest income to $51.5M. Average total assets expanded 19.0% to $1.54B, but noninterest expenses increased 12.0% to $30.1M and net interest margin compressed slightly to 3.39% from 3.46%. While taxable securities interest surged 77.3% to $21.8M, loan interest fell 3.6% to $13.3M and deposit placement services revenue plummeted 86.5% to $0.8M.

• ·Recapture of credit losses increased to $0.5M from $0.2M (205.6% YoY).
• ·Average interest-earning assets grew to $1.52B from $1.28B.
• ·Tier 1 capital, leverage, and total capital ratios not provided in excerpt.
• ·Charter effective October 3, 2024.

20-03-2026

Oblong, Inc. reported FY2025 consolidated revenue of $2.4M, up 2% YoY from $2.4M in 2024, with new Digital Assets segment contributing $0.2M (+100%) but offset by declines in Managed Services (-5% to $2.0M) and Collaboration Products (-7% to $0.3M). Gross profit surged 206% to $1.0M due to a 30% drop in cost of revenues and sharp reduction in Collaboration Products costs (-98%), however a $3.5M unrealized loss in Digital Assets drove operating expenses down only 12% while net loss widened 57% to $6.4M from $4.0M. Total assets increased 56% to $8.2M, primarily from $5.6M in Digital Assets holdings.

• ·Digital Assets represented 8% of FY2025 revenue from staking rewards.
• ·Managed Services Network services: $1.9M (78% of segment revenue) vs $2.0M prior year.
• ·Corporate operating expenses declined 10% to $3.8M.
• ·Penny stock regulations and dilution from private placements noted as risks.

20-03-2026

Total assets grew 13.7% YoY to $74.8M as of December 31, 2025, primarily driven by a 14.0% increase in premium finance contracts receivable to $72.8M, while cash rose significantly to $11.0M. Revenues increased 2.7% YoY to $12.5M with finance charges up 4.1%, however late charges declined 6.6% and origination fees fell 5.9%; net income rose 23.9% to $1.2M supported by a 6.8% drop in interest expense, though total expenses edged up 0.5%. Originations expanded 5.8% to $158.1M, with ROE improving to 17.58% from 16.57%.

• ·Allowance for credit losses increased to $2.2M from $2.0M.
• ·Line of credit interest rate decreased to 5.97% from 7.30%.
• ·Cost of funds rate (gross) improved to 7.13% from 8.36%; net to 5.35% from 6.27%.
• ·Provision for credit losses flat at +0.5%.
• ·Preferred stock dividends $116,200 in both years.

20-03-2026

AutoZone's net sales increased 8.2% YoY to $4.3B for the twelve weeks ended February 14, 2026, and 8.2% to $8.9B for the twenty-four weeks, with gross profit up 5.4% and 4.7% respectively. However, operating profit declined 1.2% to $698M and 4.2% to $1.5B YoY, resulting in net income drops of 3.9% to $469M and 5.1% to $1.0B, with diluted EPS falling to $27.63 and $58.68. The balance sheet strengthened with total assets up 5.7% to $20.4B, supported by 6.5% higher inventories at $7.5B, though operating cash flow for the twenty-four weeks decreased 5.6% to $1.3B.

• ·Capital expenditures increased 20.8% YoY to $652M for twenty-four weeks.
• ·Purchase of treasury stock $742M for twenty-four weeks, down from $866M prior year.
• ·Stockholders’ deficit improved to -$2.9B from -$3.4B.
• ·Cash and cash equivalents $285M as of Feb 14, 2026, up from $272M at Aug 30, 2025.

20-03-2026

Star Equity Holdings, Inc. reported a widened net loss attributable to common shareholders of $6.7M in 2025 versus $4.8M in 2024, with net loss increasing to $5.9M. While EBITDA loss narrowed to $2.0M from $2.5M and the new Building Solutions segment delivered $27.6M revenue, $6.3M gross profit, and $2.4M EBITDA (9% margin), Business Services revenue was flat at $139.7M YoY with gross profit up 2% to $71.8M but SG&A rising 2% to $70.4M (50% of revenue).

• ·Provision for income taxes: $2.1M in 2025 vs $1.3M in 2024
• ·Interest income, net: $(0.3)M in 2025 vs $(0.4)M in 2024
• ·Depreciation and amortization (cost of revenues): $0.9M in 2025 vs $0
• ·Depreciation and amortization (SG&A): $1.2M in 2025 vs $1.4M in 2024

20-03-2026

Lightwave Logic, Inc. reported a narrowed net loss of $20.3M for the year ended December 31, 2025, an improvement of 10% from $22.5M in 2024, supported by reduced R&D expenses to $11.5M (down 32% YoY) and higher net sales of $0.24M (up 148% YoY). However, G&A expenses increased 49% to $9.5M, contributing to ongoing operational losses, while cash burn from operations improved slightly to $13.7M from $15.6M. Total assets grew to $79.2M from $37.8M, driven by $56.9M in financing activities that boosted cash to $69.0M from $27.7M.

• ·Property and equipment net decreased to $5.2M from $5.7M.
• ·Common shares outstanding increased to 146.1M from 123.3M due to issuances and exercises.
• ·Financing activities provided $56.9M net cash in 2025 vs $14.5M in 2024.

20-03-2026

Urban One, Inc. (UONEK) reported FY 2025 net revenue of $374.4M, down 16.7% YoY from $449.7M, with declines across all major segments including radio advertising (-14.6%), political advertising (-93.0%), digital advertising (-19.0%), cable TV advertising (-9.3%), and affiliate fees (-10.0%). Net loss attributable to common stockholders widened to $146.9M from $105.4M, driven by higher impairment charges of $191.8M (up 26.4%) and increased depreciation, despite lower operating expenses in programming (-7.3%) and SG&A (-7.8%), and a larger gain on debt retirement ($44.0M, +89.1%). Adjusted EBITDA fell sharply to $56.7M from $103.5M, while core radio local advertising mix rose to 63.4% from 59.8%, but national advertising share declined to 30.7% from 35.2%.

• ·Programming and technical expenses declined 7.3% to $125.4M.
• ·Corporate SG&A expenses stable at ~$50.8M.
• ·Depreciation and amortization rose to $18.1M from $7.7M.
• ·Interest expense decreased 20.1% to $38.8M.
• ·Net cash used in investing activities $10.3M; financing $105.1M.
• ·Goodwill impairment testing (as of May 31, 2025): discount rate 9.5%, projected revenue growth (34.5)% to 53.1%.

20-03-2026

20-03-2026

Affinity Bancshares, Inc. (AFBI) reported improved asset quality in its 10-K, with total non-accrual loans declining 25% YoY to $3.57M and the non-performing loans ratio improving to 0.48% from 0.67%, while loans grew to $742.7M. Net interest income increased 6.8% to $31.1M with net interest margin expanding slightly to 3.59%, and non-interest expenses decreased 8.7% to $21.7M. However, stockholders' equity fell marginally to $127.0M from $129.1M, non-interest-bearing deposits dropped 12% to $132.8M, and retained earnings were flat at $76.1M.

• ·Net interest rate spread widened to 2.75% from 2.59%.
• ·Interest sensitivity analysis shows net interest income forecast at $32.6M at level rates, declining up to 8.27% if rates rise +400 bps.
• ·Allowance for credit losses on loans increased to $9.0M from $8.5M.
• ·Investment securities total amortized cost $43.6M at Dec 31 2025 with weighted average yield 3.53%.
• ·Common shares outstanding decreased to 6,095,631 from 6,409,598.

20-03-2026

SWK Holdings Corp reported revenues of $41.5M for 2025, down 7.8% YoY from $45.0M, contributing to a net loss of $2.5M versus $13.5M profit in 2024, amid declines in finance receivables to $218.6M (net) from $277.8M and total assets to $272.4M from $332.2M. However, cash and equivalents surged 621% to $42.8M from $5.9M, provision for credit losses improved to a $0.9M benefit from $12.8M expense, and several royalty interests and investments were sold or paid off during the year. General and administrative expenses rose 28.7% to $14.8M.

• ·Investments in Best ABT, Flowonix Medical, and Ideal Implant considered partially impaired and on non-accrual status.
• ·Several royalty interests (Forfivo XL®, Coflex®/Kybella®, Cambia®, Duo Royalty, Immune Globulin, Relief) sold as of Dec 31, 2025.
• ·Investments in Elutia Inc., Iluvien®, and MolecuLight Inc. paid off during 2025.
• ·Flowonix Medical assets sold in prior period; SWK receives royalties on two products.
• ·Property and equipment, net declined sharply to $48k from $5.438M, with most categories at zero or minimal.
• ·Allowance for credit losses: $7.278M (2025) vs $11.249M (2024).

20-03-2026

Dynamix Corp III (DNMXW), a SPAC, reported total assets of $203.9M as of December 31, 2025, including $202.5M in investments held in the Trust Account from its IPO proceeds, with cash and equivalents at $1.3M. For the period from inception (June 20, 2025) through December 31, 2025, the company recorded a net income of $0.8M, driven by $1.3M in interest and dividend income that offset a $0.5M operating loss from general and administrative costs; however, shareholders' deficit was $(6.8M) due to accretion and transaction costs related to redeemable shares.

• ·Balance sheet date: December 31, 2025; Inception date: June 20, 2025
• ·Filing date: March 20, 2026
• ·Net cash used in operating activities: $(381,923)
• ·Net cash used in investing activities: $(201.3M)
• ·Net cash provided by financing activities: $203.0M
• ·Non-cash: Offering costs paid by Sponsor for Class B shares: $25,000; Deferred underwriting fee payable: $8.1M

20-03-2026

Creative Medical Technology Holdings, Inc. (CELZ) reported a widened net loss of $6.0M for FY 2025, up 9% YoY from $5.5M in FY 2024, driven by sharply declining revenues to $6K (-45% YoY) and higher SG&A expenses (+16% YoY to $3.8M), despite reduced R&D costs (-6% YoY). Cash position strengthened to $7.2M (+21% YoY), boosting total assets to $7.8M (+17% YoY) and stockholders' equity to $7.5M (+19% YoY). The company disclosed licensing agreements including a $250K upfront royalty for ImmCelz™ and ongoing 5% royalties on net income.

• ·Licensing terms include 5% royalty on gross sales of products derived from the patent for 5 years, and 50% of sale price or ongoing payments from third-party licenses.
• ·In event of share price below $0.01 for two consecutive days, shares issuable as payment double.
• ·Sale of assets triggers one-time 10% allocation to licensor.
• ·Weighted average shares outstanding increased to 2,382,797 in FY 2025 from 1,480,420 in FY 2024; basic/diluted EPS improved to $(2.52) from $(3.71).